St. Jude Medical to highlight OCT product platform at TCT meeting

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, will highlight recently launched technology, including its new Optical Coherence Tomography (OCT) product platform, at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C. The new C7-XR™ OCT Intravascular Imaging System complements the company's PressureWire™ Fractional Flow Reserve (FFR) measurement technology platform, offering physicians a new diagnostic standard for comprehensive intravascular lesion assessment.

“St. Jude Medical is pleased to introduce the first OCT system cleared for U.S. distribution at TCT 2010”

The C7-XR OCT Intravascular Imaging System is a leading imaging technology platform that aids physicians in the diagnosis and treatment of cardiovascular disease. The C7-XR System uses near-infrared light to create high-resolution images that allow physicians to visualize and measure important vessel characteristics otherwise invisible or difficult to assess with older imaging technology. The St. Jude Medical OCT product platform expands the company's lesion assessment portfolio, which includes the recently launched PressureWire™ Aeris FFR Measurement System, and adds anatomical knowledge to the physiological information provided by FFR measurements. While FFR accurately identifies which lesions to stent, OCT-guided treatment can be especially important for the assessment of stent placement because it shows precisely how the stent is positioned against the artery wall.

"St. Jude Medical is pleased to introduce the first OCT system cleared for U.S. distribution at TCT 2010," said Frank J. Callaghan, president of the St. Jude Medical Cardiovascular Division. "Combined with our leading FFR platform, these technologies assist physicians by optimizing their patients' coronary interventions through comprehensive disease assessment, employing both anatomic and physiologic evidence. We are proud that St. Jude Medical is the first to offer both OCT and FFR technologies and we look forward to an integrated system in the future."

In addition to guiding stent selection, the C7-XR System provides physicians with post-stenting information by evaluating the position and deployment of the stent. At follow-up, the OCT technology provides detailed information regarding the inner lining of the vessel and whether there is a reoccurrence of the blood vessel narrowing.

The company's C7-XR OCT Intravascular Imaging System and PressureWire FFR measurement technology system will be demonstrated at TCT and will be on display at the St. Jude Medical booth (#1432). The St. Jude Medical Angio-Seal™ Evolution™ vascular closure device will also be featured.

OCT/FFR Virtual Reality Simulation Sessions

Physicians can learn more about OCT-guided therapy by participating in St. Jude Medical virtual reality simulations, debuting for the first time at TCT. The simulator enables physicians to manipulate the C7-XR Dragonfly™ Catheter, performing OCT-guided procedures in human-size models and selecting from a variety of case scenarios. The virtual reality sessions will take place on Sept. 23 and Sept. 24 from 9 a.m. to 5 p.m. and on Sept. 25 from 9 a.m. to 2 p.m. at the St. Jude Medical booth (#1432).

Physicians can also learn more about physiological lesion assessment by simulating the St. Jude Medical PressureWire FFR measurement technology. The FFR virtual reality sessions will take place at the St. Jude Medical booth (#1432).

Scientific Symposium

With recent clinical data and technology improvements, the incorporation of FFR and OCT into daily practice is growing at a rapid pace. To expand on the future potential of these technologies, St. Jude Medical will sponsor a scientific symposium entitled, "OCT & FFR, Current Applications, Future Potential." The symposium will take place on Thursday, Sept. 23 from 7 p.m. to 9:30 p.m. in the Renaissance Ballroom, located in the Renaissance Washington, D.C. Downtown Hotel.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
AI models show promise in predicting heart disease risks, but lack validation